Accelerate to discover

Back to filter

Related topics

Download today your IsoPlexis e-book: understanding immune Cell Function In Cancer

IsoPlexis

Dec 1, 2021

Understanding complex immune-cancer interactions is critical to identifying therapeutic targets, devising novel avenues...

IsoPlexis technology: accelerating decisions in immunotherapy with predictive single-cell response

IsoPlexis

Nov 25, 2021

The IsoLight is a hub for comprehensive functional profiling of each cell type across a large assay menu of single-cell...

Extensive assessment of Cytokine production on the NovoCyte Penteon flow cytometer

Agilent technologies

Nov 23, 2021

Cytokines are small molecules essential for immune cell response to activation by pathogens, autoimmunity, or...

Jan 26, 2022

Discover the advanced Detector Technology in Agilent NovoCyte flow cytometers

Agilent technologies

Nov 8, 2021

This technical overview describes advancements in detector technology, and highlights examples where optimal signal...

Introducing isoLight system - Automated Cellular Proteomics hub

IsoPlexis

Nov 4, 2021

The IsoLight is a hub for comprehensive functional profiling of each cell type across a large assay menu of single-cell...

Jan 26, 2022

Introducing Cytek NEW 25-Color Immunoprofiling Assay & Kit!

Cytek Biosciences

Oct 25, 2021

To unleash the power of the Cytek full spectrum cytometry system, Cytek scientists designed and developed the 25-Color...

Show all topics (10)

Morphological and pharmacological in-vitro kinetic angiogenesis assays

Nov 16, 2016

The ADSC/ECFC model yields rapidly forming (<48h) endothelial cell‘cord’structures. In the NHDF/HUVEC slowly forming‘tube-like’structures appear which continue to develop and branch even after 10days in culture. High basal formation was observed in the ADSC/ECFC model, but not in the NHDF/HUVEC model. From immuno-cytochemistry, the ADSCs surrounding the cord network label for PDGFR-β and a-SMA, suggesting apericyte phenotype.The pharmacological effects of growth factors and different pathway inhibitors were largely comparable. Interestingly, established cords and tubes display marked resistance to Avastin (Bevacizumab) compared to developing networks. G-secretase inhibition partially reversed established tubes in ADSC/ECFCs and augmented late state branching in the NHDF/HUVEC model. We conclude that these 2 models exhibit strikingly different morphological, temporal and pharmacological profiles. The resistance of established vascular structures to disruption by Avastin (Bevazicumab) may represent a useful translational paradigm for addressing tumour resistance of anti-VEGF therapies.

Read more

Scientific paper
Application
Product news

Related technologies: Real-time, label free cell analysis

Get more info

Riccardo Pasculli

Head of application support

Riccardo

Pasculli

+420 731 127 717

Send Message

Brand profile

Sartorius & Essen BioScience

Essen BioScience & Sartorius is a team of engineers and biologists with deep expertise in cell-based assays and biomolecular interaction analysis. They invent, manufacture, supply and support instrumentation, reagents and protocols.

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey